SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview as part of the RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium, which is scheduled to take place virtually on Friday, October 7, 2022.
Details of the presentation appear below:
Event: RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
Date: Friday, October 7, 2022
Time: 11:00am ET / 8:00am PT
Webcast Link: https://www.veracast.com/webcasts/rbc/lung2022/4X3iHP.cfm
The Mini-Symposium will include a series of company presentations and Key Opinion Leader (KOL) sessions in the area of pulmonary/lung disease. Planned KOL interviews include physician experts in pulmonary sarcoidosis and systemic sclerosis (SSc, also known as scleroderma)-associated interstitial lung disease, among other disease indications.
To attend aTyr’s company presentation, register at the link above. To attend the KOL sessions, investors may contact their RBC sales representative to register. Following the event, a replay of the aTyr company presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com for at least 90 days.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.
Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
[email protected]
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
